Company / SG&A Expense
PALVELLA THERAPEUTICS, INC. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.9M
FY2024
5-year range
$3.1M / $18.4M
FY2020-FY2024
Trend
+93.2%
vs FY2023
Sector context
#212 of 213
Health Care
What the data says
Among 213 Health Care companies, PALVELLA THERAPEUTICS, INC. is in the top 1% for sg&a expense. SG&A Expense returned to growth in FY2024 after 3 years of decline, reaching $6M.
Based on SEC 10-K filings.
$6M in FY2024 with a 5-year CAGR of -20.3%.
Improved from $16M to $6M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -29.1%
- 5-Year CAGR
- -20.3%
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 213This company $5.9M Sector average $722.3M
▼
-99.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.3%, indicating a declining trend.
- In FY2024, sg&a expense increased 93.2% year-over-year.
- Ranks #212 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $5.9M | +93.2% |
| FY2023 | $3.1M | -81.2% |
| FY2022 | $16.4M | -1.9% |
| FY2021 | $16.7M | -9.4% |
| FY2020 | $18.4M | +0.0% |
| FY2019 | $18.4M | +4.9% |
| FY2018 | $17.6M | +97.8% |
| FY2017 | $8.9M | +0.0% |
| FY2016 | $8.9M | +6.2% |
| FY2015 | $8.4M | +20.2% |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026